login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
BRIACELL THERAPEUTICS - 30 (BCTXZ) Stock News
NASDAQ:BCTXZ - Nasdaq -
- Currency: USD
0.3399
+0.03 (+9.68%)
Summary
Stock Chart
Technical Analysis
News
BCTXZ Latest News, Press Relases and Analysis
All
Press Releases
4 hours ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Awarded New Zealand Patent for its Whole Cell Technology
a day ago - By: BriaCell Therapeutics Corp.; BriaPro Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell’s Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents
5 days ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025
14 days ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Therapeutics Announces Closing of $15 million Public Offering
15 days ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Therapeutics Announces Pricing of $15 million Public Offering
15 days ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer
19 days ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell’s Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer
20 days ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient
21 days ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study
22 days ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer
a month ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven
a month ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer
2 months ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26
2 months ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025
Please enable JavaScript to continue using this application.
